Figure 2. Regarding pediatric AML patients with EMI at initial
diagnosis, event free survival (EFS) and overall survival (OS) of
patients underwent SCT or not (A, B); EFS and OS of patients underwent
GO treatment or not (C, D).
Univariate and multivariate analysis of impact factors for
prognosis
In accordance with univariate analysis, apart from the EMI at diagnosis,
thirteen factors (Table 3), were considered as covariates in the Cox
models due to their potential to impact the prognosis of pediatric AML
patients. These factors encompassed age ≤2 years, WBC
≥100×109/L, t(8;21), inv(16), del5q/del7q/-5/-7,
trisomy 8/trisomy 21, minus X/minus Y, CEBPA +, FLT3
ITD-/NPM1+ , FLT3 ITD+ , WT1+ , KMT2A rearrangements,
NUP98 fusion, SCT and GO treatment. The multivariate analysis
demonstrated that EMI at diagnosis emerged as an independent prognostic
risk factor for both shorter OS (HR 1.425, 95% CI 1.033-1.964,
p=0.0307) and EFS (HR 1.672, 95% CI 1.283-2.179, p=0.0001).
Furthermore, WBC ≥100×109/L, WT1+ , and
del5q/del7q/-5/-7 were identified as independent predictors of poorer
outcomes. Conversely, the remaining five factors, including t(8;21),
inv(16), CEBPA+ , FLT3 ITD-/NPM1+ , and SCT, were associated
with improved survival (Table 3).
Table 3. Univariate and multivariate analysis of OS and EFS in
pediatric AML patients.